These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63 related articles for article (PubMed ID: 7274779)
21. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Kitchen S; Iampietro R; Woolley AM; Preston FE Thromb Haemost; 1999 Oct; 82(4):1289-93. PubMed ID: 10544915 [TBL] [Abstract][Full Text] [Related]
22. comparison of clot-based vs chromogenic factor Xa procoagulant phospholipid activity assays. Bohling SD; Pagano MB; Stitzel MR; Ferrell C; Yeung W; Chandler WL Am J Clin Pathol; 2012 Feb; 137(2):185-92. PubMed ID: 22261442 [TBL] [Abstract][Full Text] [Related]
23. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma. Ofosu FA; Lormeau JC; Craven S; Dewar L; Anvari N Thromb Haemost; 1994 Dec; 72(6):862-8. PubMed ID: 7740455 [TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation. Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212 [TBL] [Abstract][Full Text] [Related]
25. Lack of agreement of chromogenic and clotting assays for factor X and protein C in warfarinised plasma. Han P; Fung KP; Rahdakrishnan U Thromb Haemost; 1991 Apr; 65(4):360-3. PubMed ID: 2057917 [TBL] [Abstract][Full Text] [Related]
26. The antiheparin effect of alpha 1-acid glycoprotein, evaluated by the activated partial thromboplastin time and by a factor Xa assay for heparin. Andersen P Haemostasis; 1980; 9(5):303-9. PubMed ID: 7409614 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of Factor Xa-Specific Chromogenic Substrate Assays and the Determination of Pharmacokinetics of Fondaparinux. Yuri M; Tabe Y; Tsuchiya K; Sadatsuki R; Aoki J; Horii T; Iba T; Ohsaka A Clin Appl Thromb Hemost; 2016 Jul; 22(5):453-8. PubMed ID: 26177660 [TBL] [Abstract][Full Text] [Related]
28. A method for measuring activated factor VIII in plasma. Kessels H; Béguin S; Wagenvoord R; Hemker HC Thromb Haemost; 1991 Oct; 66(4):430-4. PubMed ID: 1796392 [TBL] [Abstract][Full Text] [Related]
29. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*. Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992 [TBL] [Abstract][Full Text] [Related]
30. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Becker RC; Alexander JH; Newby LK; Yang H; Barrett Y; Mohan P; Wang J; Harrington RA; Wallentin LC Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117 [TBL] [Abstract][Full Text] [Related]
31. Dual effect of Platelet Factor 4 on the activities of Factor Xa. Fiore MM; Mackie IJ Biochem Biophys Res Commun; 2009 Feb; 379(4):1072-5. PubMed ID: 19150337 [TBL] [Abstract][Full Text] [Related]
32. Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide. Douxfils J; Chatelain B; Chatelain C; Dogné JM; Mullier F Thromb Haemost; 2016 Jan; 115(2):368-81. PubMed ID: 26510969 [TBL] [Abstract][Full Text] [Related]
33. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Kitchen S; Theaker J; Preston FE Blood Coagul Fibrinolysis; 2000 Mar; 11(2):137-44. PubMed ID: 10759006 [TBL] [Abstract][Full Text] [Related]
34. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass. Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414 [TBL] [Abstract][Full Text] [Related]
35. Assay for endogenous heparin in plasma of livestock using a synthetic chromogenic substrate. Ledwozyw A; Jabłonka S; Tusińska E; Herbut M Arch Vet Pol; 1993; 33(3-4):269-73. PubMed ID: 10187992 [TBL] [Abstract][Full Text] [Related]
36. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Mani H; Hesse C; Stratmann G; Lindhoff-Last E Thromb Haemost; 2013 Jan; 109(1):127-36. PubMed ID: 23138190 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of human coagulation factor Xa by thrombin substrates. Orthner CL; Morris S; Kosow DP Thromb Res; 1981 Sep; 23(6):533-9. PubMed ID: 7324010 [No Abstract] [Full Text] [Related]
38. Factor Xa and thrombin evoke additive calcium and proinflammatory responses in endothelial cells subjected to coagulation. Daubie V; Cauwenberghs S; Senden NH; Pochet R; Lindhout T; Buurman WA; Heemskerk JW Biochim Biophys Acta; 2006 Aug; 1763(8):860-9. PubMed ID: 16765466 [TBL] [Abstract][Full Text] [Related]
39. Formation of the fibrin clot: the balance of procoagulant and inhibitory factors. Lämmle B; Griffin JH Clin Haematol; 1985 Jun; 14(2):281-342. PubMed ID: 2994929 [TBL] [Abstract][Full Text] [Related]
40. Automated instrumentation and the laboratory diagnosis of bleeding and thrombotic disorders. Walenga J; Fareed J; Bermes EW Semin Thromb Hemost; 1983 Jul; 9(3):172-93. PubMed ID: 6351253 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]